129 related articles for article (PubMed ID: 37080059)
21. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D
Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414
[TBL] [Abstract][Full Text] [Related]
22. Modified National Comprehensive Cancer Network Criteria for Assessing Resectability of Pancreatic Ductal Adenocarcinoma.
Noda Y; Goshima S; Kawada H; Kawai N; Miyoshi T; Matsuo M; Bae KT
AJR Am J Roentgenol; 2018 Jun; 210(6):1252-1258. PubMed ID: 29629801
[TBL] [Abstract][Full Text] [Related]
23. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resection vs CT-determined resectability.
Jang JK; Choi SJ; Byun JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Hwang DW; Kim SC
J Hepatobiliary Pancreat Sci; 2022 Sep; 29(9):1025-1034. PubMed ID: 35658103
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy generates a significant tumor response in resectable pancreatic cancer without increasing morbidity: results of a prospective phase II trial.
Heinrich S; Schäfer M; Weber A; Hany TF; Bhure U; Pestalozzi BC; Clavien PA
Ann Surg; 2008 Dec; 248(6):1014-22. PubMed ID: 19092346
[TBL] [Abstract][Full Text] [Related]
25. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
[TBL] [Abstract][Full Text] [Related]
26. CT response of primary tumor and CA19-9 predict resectability of metastasized pancreatic cancer after FOLFIRINOX.
Tanaka M; Heckler M; Mihaljevic AL; Sun H; Klaiber U; Heger U; Büchler MW; Hackert T
Eur J Surg Oncol; 2019 Aug; 45(8):1453-1459. PubMed ID: 30981446
[TBL] [Abstract][Full Text] [Related]
27. Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria.
Hong SB; Lee SS; Kim JH; Kim HJ; Byun JH; Hong SM; Song KB; Kim SC
Radiology; 2018 Dec; 289(3):710-718. PubMed ID: 30251929
[TBL] [Abstract][Full Text] [Related]
28. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
29. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head.
Heinrich S; Pestalozzi BC; Schäfer M; Weber A; Bauerfeind P; Knuth A; Clavien PA
J Clin Oncol; 2008 May; 26(15):2526-31. PubMed ID: 18487569
[TBL] [Abstract][Full Text] [Related]
30. NeoGemTax: gemcitabine and docetaxel as neoadjuvant treatment for locally advanced nonmetastasized pancreatic cancer.
Sahora K; Kuehrer I; Schindl M; Koelblinger C; Goetzinger P; Gnant M
World J Surg; 2011 Jul; 35(7):1580-9. PubMed ID: 21523499
[TBL] [Abstract][Full Text] [Related]
31. Detecting tumour response and predicting resectability after neoadjuvant therapy for borderline resectable and locally advanced pancreatic cancer.
Barreto SG; Loveday B; Windsor JA; Pandanaboyana S
ANZ J Surg; 2019 May; 89(5):481-487. PubMed ID: 30117669
[TBL] [Abstract][Full Text] [Related]
32. CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis.
Park S; Jang JK; Byun JH; Kim JH; Lee SS; Kim HJ; Hong SB; Park SH
Eur Radiol; 2021 May; 31(5):3383-3393. PubMed ID: 33123793
[TBL] [Abstract][Full Text] [Related]
33. Preoperative assessment of the resectability of pancreatic ductal adenocarcinoma on CT according to the NCCN Guidelines focusing on SMA/SMV branch invasion.
Park SJ; Jang S; Han JK; Kim H; Kwon W; Jang JY; Lee KB; Kim H; Lee DH
Eur Radiol; 2021 Sep; 31(9):6889-6897. PubMed ID: 33740095
[TBL] [Abstract][Full Text] [Related]
34. Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma.
Quan K; Sutera P; Xu K; Bernard ME; Burton SA; Wegner RE; Zeh H; Bahary N; Stoller R; Heron DE
Pract Radiat Oncol; 2018; 8(2):95-106. PubMed ID: 29291966
[TBL] [Abstract][Full Text] [Related]
35. Radiological Downstaging with Neoadjuvant Therapy in Unresectable Gall Bladder Cancer Cases.
Agrawal S; Mohan L; Mourya C; Neyaz Z; Saxena R
Asian Pac J Cancer Prev; 2016; 17(4):2137-40. PubMed ID: 27221908
[TBL] [Abstract][Full Text] [Related]
36. Intraoperative Ultrasound During Surgical Exploration in Patients with Pancreatic Cancer and Vascular Involvement (ULTRAPANC): A Prospective Multicenter Study.
Michiels N; Doppenberg D; Groen JV; van Veldhuisen E; Bonsing BA; Busch OR; Crobach ASLP; van Delden OM; van Dieren S; Farina A; de Hingh IHJT; Hurks R; Nederend J; Shahbazi Feshtali S; Tank Y; Vahrmeijer AL; Wasser M; Besselink MG; Mieog JSD;
Ann Surg Oncol; 2023 Jun; 30(6):3455-3463. PubMed ID: 36774435
[TBL] [Abstract][Full Text] [Related]
37. Pancreatic adenocarcinoma: A simple CT score for predicting margin-positive resection in patients with resectable disease.
Cassinotto C; Dohan A; Zogopoulos G; Chiche L; Laurent C; Sa-Cunha A; Cuggia A; Reinhold C; Gallix B
Eur J Radiol; 2017 Oct; 95():33-38. PubMed ID: 28987689
[TBL] [Abstract][Full Text] [Related]
38. Predicting resection margin status of pancreatic neuroendocrine tumors on CT: performance of NCCN resectability criteria.
Kim DH; Kim B; Chung DJ; Kim KA; Lee SL; Choi MH; Kim H; Rha SE
Br J Radiol; 2023 Dec; 96(1152):20230503. PubMed ID: 37750830
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study).
Heinrich S; Pestalozzi B; Lesurtel M; Berrevoet F; Laurent S; Delpero JR; Raoul JL; Bachellier P; Dufour P; Moehler M; Weber A; Lang H; Rogiers X; Clavien PA
BMC Cancer; 2011 Aug; 11():346. PubMed ID: 21831266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]